Main Publication
-
Efficacy of Nrf2 activation in a proteinuric Alport syndrome mouse model.
Kaseda S, Horizono J, Sannomiya Y, Kuwazuru J, Suico MA, Sato R, Fukiya H, Sunamoto H, Ogi S, Matsushita T, Koyama Y, Owaki A, Tsuhako H, Shiraga M, Watanabe H, Nakano T, Davenport B, Nozu K, Yamamoto M, Shuto T, Tokunaga Y, Lennon R, Onuma K, Kai H.
Life Sci Alliance. 2025 Jun 17;8(8):e202503330. doi: 10.26508/lsa.202503330.
https://www.life-science-alliance.org/content/8/8/e202503330
Related Publications
-
CyclosporinA Derivative as Therapeutic Candidate for Alport Syndrome by Inducing Mutant Type IV Collagen Secretion
Kuwazuru J, Suico MA, Omachi K, Kojima H, Kamura M, Kaseda S, Kawahara T, Hitora Y, Kato H, Tsukamoto S, Wada M, Asano T, Kotani S, Nakajima M, Misumi S, Sannomiya Y, Horizono J, Koyama Y, Owaki A, Shuto T, Kai H.Kidney360. 2023 Jul 1;4(7):909-917. doi: 10.34067/KID.0000000000000134. Epub 2023 May 5.PMID:37143203 -
Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model
Kaseda S, Sannomiya Y, Horizono J, Kuwazuru J, Suico MA, Ogi S, Sasaki R, Sunamoto H, Fukiya H, Nishiyama H, Kamura M, Niinou S, Koyama Y, Nara F, Shuto T, Onuma K, Kai H.Kidney360. 2021 Dec 1;3(4):687-699. doi: 10.34067/KID.0004572021. eCollection 2022 Apr 28.PMID:35721612 -
The 2019 and 2021 International Workshops on Alport Syndrome
Daga S, Ding J, Deltas C, Savige J, Lipska-Ziętkiewicz BS, Hoefele J, Flinter F, Gale DP, Aksenova M, Kai H, Perin L, Barua M, Torra R, Miner JH, Massella L, Ljubanović DG, Lennon R, Weinstock AB, Knebelmann B, Cerkauskaite A, Gear S, Gross O, Turner AN, Baldassarri M, Pinto AM, Renieri A.Eur J Hum Genet. 2022 May;30(5):507-516. doi: 10.1038/s41431-022-01075-0. Epub 2022 Mar 9.PMID:35260866 -
NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough
Omachi K, Kai H, Roberge M, Miner JH.iScience. 2022 Feb 8;25(3):103891. doi: 10.1016/j.isci.2022.103891. eCollection 2022 Mar 18.PMID:35243249 -
Type IV Collagen Variants in CKD: Performance of Computational Predictions for Identifying Pathogenic Variants
Shulman C, Liang E, Kamura M, Udwan K, Yao T, Cattran D, Reich H, Hladunewich M, Pei Y, Savige J, Paterson AD, Suico MA, Kai H, Barua M.Kidney Med. 2021 Feb 10;3(2):257-266. doi: 10.1016/j.xkme.2020.12.007. eCollection 2021 Mar-Apr.PMID:33851121 -
Metformin ameliorates the severity of experimental Alport syndrome
Omachi K, Kaseda S, Yokota T, Kamura M, Teramoto K, Kuwazuru J, Kojima H, Nohara H, Koyama K, Ohtsuki S, Misumi S, Takeo T, Nakagata N, Li JD, Shuto T, Suico MA, Miner JH, Kai H.Sci Rep. 2021 Mar 29;11(1):7053. doi: 10.1038/s41598-021-86109-1.PMID:33782421 -
The role of discoidin domain receptor 2 in the renal dysfunction of alport syndrome mouse model
Sannomiya Y, Kaseda S, Kamura M, Yamamoto H, Yamada H, Inamoto M, Kuwazuru J, Niino S, Shuto T, Suico MA, Kai H.Ren Fail. 2021 Dec;43(1):510-519. doi: 10.1080/0886022X.2021.1896548.PMID:33706638 -
Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome
Nozu K, Takaoka Y, Kai H, Takasato M, Yabuuchi K, Yamamura T, Horinouchi T, Sakakibara N, Ninchoji T, Nagano C, Iijima K.Kidney Res Clin Pract. 2020 Dec 31;39(4):402-413. doi: 10.23876/j.krcp.20.111.PMID:33214343 - Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5
Yamamura T, Horinouchi T, Adachi T, Terakawa M, Takaoka Y, Omachi K, Takasato M, Takaishi K, Shoji T, Onishi Y, Kanazawa Y, Koizumi M, Tomono Y, Sugano A, Shono A, Minamikawa S, Nagano C, Sakakibara N, Ishiko S, Aoto Y, Kamura M, Harita Y, Miura K, Kanda S, Morisada N, Rossanti R, Ye MJ, Nozu Y, Matsuo M, Kai H, Iijima K, Nozu K.Nat Commun. 2020 Jun 2;11(1):2777. doi: 10.1038/s41467-020-16605-x.PMID:32488001 - Trimerization and Genotype-Phenotype Correlation of COL4A5 Mutants in Alport Syndrome
Kamura M, Yamamura T, Omachi K, Suico MA, Nozu K, Kaseda S, Kuwazuru J, Shuto T, Iijima K, Kai H.Kidney Int Rep. 2020 Jan 30;5(5):718-726. doi: 10.1016/j.ekir.2020.01.008. eCollection 2020 May.PMID:32405592 - A Split-Luciferase-Based Trimer Formation Assay as a High-throughput Screening Platform for Therapeutics in Alport Syndrome
Omachi K, Kamura M, Teramoto K, Kojima H, Yokota T, Kaseda S, Kuwazuru J, Fukuda R, Koyama K, Matsuyama S, Motomura K, Shuto T, Suico MA, Kai H.Cell Chem Biol. 2018 May 17;25(5):634-643.e4. doi: 10.1016/j.chembiol.2018.02.003. Epub 2018 Mar 8.PMID:29526710 - Clinical trial recommendations for potential Alport syndrome therapies
Weinstock BA, Feldman DL, Fornoni A, Gross O, Kashtan CE, Lagas S, Lennon R, Miner JH, Rheault MN, Simon JF; Workshop Participants.Kidney Int. 2020 Jun;97(6):1109-1116. doi: 10.1016/j.kint.2020.02.029. Epub 2020 Apr 6.PMID:32386680 - STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model
Yokota T, Omachi K, Suico MA, Kamura M, Kojima H, Fukuda R, Motomura K, Teramoto K, Kaseda S, Kuwazuru J, Takeo T, Nakagata N, Shuto T, Kai H.Nephrol Dial Transplant. 2018 Feb 1;33(2):214-223. doi: 10.1093/ndt/gfx246.PMID:28992339 - Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome
Yokota T, Omachi K, Suico MA, Kojima H, Kamura M, Teramoto K, Kaseda S, Kuwazuru J, Shuto T, Kai H.PLoS One. 2017 Sep 5;12(9):e0183959. doi: 10.1371/journal.pone.0183959. eCollection 2017.PMID:28873450 - Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model
Omachi K, Miyakita R, Fukuda R, Kai Y, Suico MA, Yokota T, Kamura M, Shuto T, Kai H.Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse modelClin Exp Nephrol. 2017 Dec;21(6):952-960. doi: 10.1007/s10157-017-1386-9. Epub 2017 Feb 8.PMID:28176019 - Podocyte p53 Limits the Severity of Experimental Alport Syndrome
Fukuda R, Suico MA, Kai Y, Omachi K, Motomura K, Koga T, Komohara Y, Koyama K, Yokota T, Taura M, Shuto T, Kai H.J Am Soc Nephrol. 2016 Jan;27(1):144-57. doi: 10.1681/ASN.2014111109. Epub 2015 May 12.PMID:25967122 - Mild electrical stimulation and heat shock ameliorates progressive proteinuria and renal inflammation in mouse model of Alport syndrome
Koga T, Kai Y, Fukuda R, Morino-Koga S, Suico MA, Koyama K, Sato T, Shuto T, Kai H.PLoS One. 2012;7(8):e43852. doi: 10.1371/journal.pone.0043852. Epub 2012 Aug 24.PMID:22937108